Salvage chemotherapy followed by autoSCT for relapsed HIV associated lymphoma

Phase 2

• Conditions: Relapsed or refractory HIV associated lymphoma

• Registration Number: JPRN-UMIN000001181
• Lead Sponsor: International Medical Center of JAPA

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-06-10
• Study Completion: 2014-06-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

Exclusion criteria for salvage regimen 1)Organ dysfunction a)EF<40% by cardiac sonography b)PaO2<50mmHg or SaO2<90% c)serumCr>3.0mg/dl d)Total-bilirubin>3.0mg/dl or ALT>five times upper limit of the institutional normal value 2)Serious active infection Exclusion criteria for PBSCT 1)Organ dysfunction a)EF<50% by cardiac sonography b)PaO2<60mmHg c)serumCr>2.0mg/dl d)Total-bilirubin>2.0mg/dl or ALT>twice of upper limit of the institutional normal value 2)Uncontrollable HIV virus load and resistant to HAART 3)Uncontrollable diabetes which is resistant to insulin 4)Uncontrollable hypertension 5)Intractable and active infection 6)Intractable invasion of lymphoma to CNS 7)Pregnant or possible pregnant women or breast feeding

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
2year over all survival

Secondary Outcome Measures

Name	Time	Method
survival at 100 days after transplantation, CR rate, therapy related toxicity, the number of collected stem cells, the rate of engraftment, the number of CD4 positive cells, the quantity of HIV-virus